» Articles » PMID: 18665258

Protection Induced by Plasmodium Falciparum MSP1(42) is Strain-specific, Antigen and Adjuvant Dependent, and Correlates with Antibody Responses

Abstract

Vaccination with Plasmodium falciparum MSP1(42)/complete Freund's adjuvant (FA) followed by MSP1(42)/incomplete FA is the only known regimen that protects Aotus nancymaae monkeys against infection by erythrocytic stage malaria parasites. The role of adjuvant is not defined; however complete FA cannot be used in humans. In rodent models, immunity is strain-specific. We vaccinated Aotus monkeys with the FVO or 3D7 alleles of MSP1(42) expressed in Escherichia coli or with the FVO allele expressed in baculovirus (bv) combined with complete and incomplete FA, Montanide ISA-720 (ISA-720) or AS02A. Challenge with FVO strain P. falciparum showed that suppression of cumulative day 11 parasitemia was strain-specific and could be induced by E. coli expressed MSP1(42) in combination with FA or ISA-720 but not with AS02A. The coli42-FVO antigen induced a stronger protective effect than the bv42-FVO antigen, and FA induced a stronger protective effect than ISA-720. ELISA antibody (Ab) responses at day of challenge (DOC) were strain-specific and correlated inversely with c-day 11 parasitemia (r = -0.843). ELISA Ab levels at DOC meeting a titer of at least 115,000 ELISA Ab units identified the vaccinees not requiring treatment (noTx) with a true positive rate of 83.3% and false positive rate of 14.3 %. Correlation between functional growth inhibitory Ab levels (GIA) and cumulative day 11 parasitemia was weaker (r = -0.511), and was not as predictive for a response of noTx. The lowest false positive rate for GIA was 30% when requiring a true positive rate of 83.3%. These inhibition results along with those showing that antigen/FA combinations induced a stronger protective immunity than antigen/ISA-720 or antigen/AS02 combinations are consistent with protection as ascribed to MSP1-specific cytophilic antibodies. Development of an effective MSP1(42) vaccine against erythrocytic stage P. falciparum infection will depend not only on antigen quality, but also upon the selection of an optimal adjuvant component.

Citing Articles

Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum.

Ciubotariu I, Broyles B, Xie S, Thimmapuram J, Mwenda M, Mambwe B EBioMedicine. 2024; 106:105227.

PMID: 39018754 PMC: 11663769. DOI: 10.1016/j.ebiom.2024.105227.


Natural Infection Stimulates Human Antibodies to MSP1 Epitopes Identified in Mice Infection Models upon Non-Natural Modified Peptidomimetic Vaccination.

Rodriguez Z, Melo F, Torres A, Agrawal N, Cortes-Vecino J, Lozano J Molecules. 2023; 28(6).

PMID: 36985500 PMC: 10057838. DOI: 10.3390/molecules28062527.


Orientation of Antigen Display on Self-Assembling Protein Nanoparticles Influences Immunogenicity.

Schneider C, Taylor J, Sibilo M, Miura K, Mallory K, Mann C Vaccines (Basel). 2021; 9(2).

PMID: 33572803 PMC: 7911071. DOI: 10.3390/vaccines9020103.


The Search of a Malaria Vaccine: The Time for Modified Immuno-Potentiating Probes.

Lozano J, Rodriguez Parra Z, Hernandez-Martinez S, Fernanda Yasnot-Acosta M, Rojas A, Marin-Waldo L Vaccines (Basel). 2021; 9(2).

PMID: 33540947 PMC: 7913233. DOI: 10.3390/vaccines9020115.


Plasmodium vivax Pv12 B-cell epitopes and HLA-DRβ1*-dependent T-cell epitopes in vitro antigenicity.

Yepes-Perez Y, Lopez C, Suarez C, Patarroyo M PLoS One. 2018; 13(9):e0203715.

PMID: 30199554 PMC: 6130872. DOI: 10.1371/journal.pone.0203715.


References
1.
Chang S, Case S, Gosnell W, Hashimoto A, Kramer K, Tam L . A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun. 1996; 64(1):253-61. PMC: 173753. DOI: 10.1128/iai.64.1.253-261.1996. View

2.
Angov E, Hillier C, Kincaid R, Lyon J . Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS One. 2008; 3(5):e2189. PMC: 2364656. DOI: 10.1371/journal.pone.0002189. View

3.
Darko C, Angov E, Collins W, Bergmann-Leitner E, Girouard A, Hitt S . The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun. 2004; 73(1):287-97. PMC: 538964. DOI: 10.1128/IAI.73.1.287-297.2005. View

4.
Blackman M, Holder A . Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol. 1992; 50(2):307-15. DOI: 10.1016/0166-6851(92)90228-c. View

5.
Stoute J, Slaoui M, Heppner D, Momin P, Kester K, Desmons P . A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997; 336(2):86-91. DOI: 10.1056/NEJM199701093360202. View